Clincosm LogoSign in Get a demo

Recurrent Breast Carcinoma

Showing 26 - 50 of 64
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Malignant Solid Tumor, Estrogen Receptor Positive, HER2/Neu Positive Trial in United States (drug, other, biological)

Completed
  • Advanced Malignant Solid Neoplasm
  • +12 more
  • Houston, Texas
  • +4 more
Dec 16, 2020

Breast Adenocarcinoma, Estrogen Receptor Positive, HER2/Neu Negative Trial in Tampa, Bronx (drug, other, procedure)

Terminated
  • Breast Adenocarcinoma
  • +8 more
  • Tampa, Florida
  • +1 more
Sep 22, 2020

Recurrent Breast Carcinoma, Stage IV Breast Cancer Trial in United States (Eribulin Mesylate, Laboratory Biomarker Analysis)

Completed
Has Results
  • Recurrent Breast Carcinoma
  • Stage IV Breast Cancer
  • Eribulin Mesylate
  • Laboratory Biomarker Analysis
  • Anchorage, Alaska
  • +11 more
Jul 10, 2020

Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative Trial in Chicago, Lake Forest (drug, other,

Unknown status
Has Results
  • Estrogen Receptor Negative
  • +9 more
  • Chicago, Illinois
  • +1 more
Jun 25, 2020

Breast Carcinoma Metastatic in the Brain, Estrogen Receptor Negative, HER2/Neu Negative Trial in Chicago, Lake Forest, Houston

Terminated
Has Results
  • Breast Carcinoma Metastatic in the Brain
  • +6 more
  • Cognitive Assessment
  • +3 more
  • Chicago, Illinois
  • +2 more
Apr 2, 2020

HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7 Trial in United States (drug,

Completed
Has Results
  • HER2 Positive Breast Carcinoma
  • +4 more
  • Mobile, Alabama
  • +389 more
Mar 11, 2020

Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7 Trial in Chicago, Saint Louis

Completed
Has Results
  • Recurrent Breast Carcinoma
  • +5 more
  • Chicago, Illinois
  • +1 more
Feb 13, 2020

Estrogen Receptor Positive, HER2 Positive Breast Carcinoma, HER2/Neu Negative Trial in United States (Fulvestrant, Laboratory

Completed
Has Results
  • Estrogen Receptor Positive
  • +7 more
  • Little Rock, Arkansas
  • +367 more
Dec 9, 2019

Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma Trial in United States (Akt Inhibitor GSK2141795,

Completed
Has Results
  • Estrogen Receptor Negative
  • +6 more
  • Akt Inhibitor GSK2141795
  • +2 more
  • Washington, District of Columbia
  • +7 more
Aug 27, 2019

Advanced Malignant Tumor, Cervical Squamous Cell Carcinoma, Endometrial Carcinoma Trial in Scottsdale, Rochester (Laboratory

Completed
  • Advanced Malignant Neoplasm
  • +31 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Scottsdale, Arizona
  • +1 more
Jun 5, 2019

HER2/Neu Positive, Invasive Breast Carcinoma, Recurrent Breast Carcinoma Trial in Houston (drug, other, biological)

Completed
  • HER2/Neu Positive
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
May 17, 2019

Estrogen Receptor Negative, HER2/Neu Negative, Metastatic Breast Cancer Trial in Seattle (Pembrolizumab, Cisplatin)

Withdrawn
  • Estrogen Receptor Negative
  • +5 more
  • Seattle, Washington
    Seattle Cancer Care Alliance, Fred Hutch/University of Washingto
Apr 24, 2019

Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer Trial in United States (Akt Inhibitor MK2206,

Completed
Has Results
  • Recurrent Breast Carcinoma
  • +3 more
  • Akt Inhibitor MK2206
  • +2 more
  • Boston, Massachusetts
  • +4 more
Nov 28, 2018

Estrogen Receptor Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma Trial in Rochester (Alisertib,

Completed
  • Estrogen Receptor Positive
  • +5 more
  • Rochester, Minnesota
    Mayo Clinic
Oct 2, 2018

Estrogen Receptor Positive, Invasive Breast Carcinoma, Recurrent Breast Carcinoma Trial in Saint Louis (Akt Inhibitor MK2206,

Completed
  • Estrogen Receptor Positive
  • +3 more
  • Akt Inhibitor MK2206
  • +3 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Jul 20, 2018

Basal-Like Breast Carcinoma, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier Trial in United States (Laboratory Biomarker

Completed
  • Basal-Like Breast Carcinoma
  • +16 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Duarte, California
  • +6 more
Jun 28, 2018

Male Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7 Trial in United States (biological,

Completed
Has Results
  • Male Breast Carcinoma
  • +2 more
  • Cixutumumab
  • +3 more
  • Palo Alto, California
  • +191 more
May 15, 2018

Estrogen Receptor Positive, HER2/Neu Negative, Recurrent Breast Carcinoma Trial in United States (drug, other, procedure)

Terminated
Has Results
  • Estrogen Receptor Positive
  • +7 more
  • Akt Inhibitor MK2206
  • +6 more
  • Scottsdale, Arizona
  • +7 more
Apr 6, 2018

BRCA1 Gene Mutation, BRCA2 Gene Mutation, Estrogen Receptor Negative Trial in Bronx, Columbus (drug, other, procedure)

Completed
  • BRCA1 Gene Mutation
  • +11 more
  • Bronx, New York
  • +2 more
Apr 20, 2018

Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma Trial in Houston (Dinaciclib, Epirubicin Hydrochloride,

Completed
  • Estrogen Receptor Negative
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Mar 29, 2018

Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma Trial in Bronx, New York (Laboratory Biomarker Analysis,

Completed
  • Estrogen Receptor Negative
  • +9 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Bronx, New York
  • +5 more
Dec 21, 2017

Estrogen Receptor Positive, Male Breast Carcinoma, Progesterone Receptor Positive Trial in Detroit (Laboratory Biomarker

Completed
Has Results
  • Estrogen Receptor Positive
  • +6 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Detroit, Michigan
  • +1 more
Oct 27, 2017

HER2/Neu Positive, Recurrent Breast Carcinoma, Stage IV Breast Cancer Trial in Seattle (HER-2/neu Intracellular Domain Protein,

Unknown status
  • HER2/Neu Positive
  • +2 more
  • HER-2/neu Intracellular Domain Protein
  • +5 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Sep 27, 2017

Adult Solid Tumor, Recurrent Breast Carcinoma, Stage IV Breast Cancer Trial in Boston, Nashville, Houston (Akt Inhibitor MK2206,

Completed
  • Adult Solid Neoplasm
  • +2 more
  • Akt Inhibitor MK2206
  • +3 more
  • Boston, Massachusetts
  • +2 more
Aug 24, 2017

Recurrent Breast Carcinoma, Stage IV Breast Cancer Trial in San Francisco, New York (biological, drug, other)

Completed
Has Results
  • Recurrent Breast Carcinoma
  • Stage IV Breast Cancer
  • Bevacizumab
  • +2 more
  • San Francisco, California
  • +1 more
Jun 23, 2017